Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 483-489

  Rababah, Munir ^a   Worthmann, Hans ^a   Deb, Milani ^a   Tryc, Anita B ^a   Ma, Yue Tao ^a,b   El Bendary, Omnia M ^a,c   Hecker, Hartmut ^a   Goldbecker, Annemarie ^a   Heeren, Meike ^a   Brand, Korbinian ^a   Weissenborn, Karin ^a   Lichtinghagen, Ralf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

Author keywords

Anticoagulant; Matrix metalloproteinase 9; Mononuclear leukocytes; Pre analytic procedure; Stroke

Indexed keywords

ANTICOAGULANT AGENT; CITRIC ACID; EDETIC ACID; GELATINASE B; HEPARIN; MESSENGER RNA; PROTEINASE INHIBITOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; MEDICAL HISTORY; MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEX DIFFERENCE; SMOKING; STROKE; STROKE PATIENT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTIFACTS; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; CITRIC ACID; ENZYME STABILITY; FEMALE; HEPARIN; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; STROKE; TRANSCRIPTION, GENETIC;

EID: 84862800136     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.028     Document Type: Article

References (35)

1. Reynolds M.A., Kirchick H.J., Dahlen J.R., Anderberg J.M., McPherson P.H., Nakamura K.K., et al. Early biomarkers of stroke. Clin Chem 2003, 49:1733-1739.
2. Castellanos M., Rogelio L., Joaquín S., José M.P., Ignacio L., José C., et al. Plasma Metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34:40-46.
3. Zhao B.Q., Ikeda Y., Ihara H., Urano T., Fan W., Mikawa S., et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004, 103:2610-2616.
4. Ning M., Furie K.L., Koroshetz W.J., Lee H., Barron M., Lederer M., et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 2006, 66:1550-1555.
5. Morancho A., Rosell A., García-Bonilla L., Montaner J. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment?. Ann N Y Acad Sci 2010, 1207:123-133.
6. Montaner J., Alvarez-Sabín J., Molina C., Anglés A., Abilleira S., Arenillas J., et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001, 32:1759-1766.
7. Serena J., Blanco M., Castellanos M., Silva Y., Vivancos J., Moro M.A., et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005, 36:1921-1926.
8. Barr T.L., Latour L.L., Lee K.Y., Schaewe T.J., Luby M., Chang G.S., et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010, 41(3):e123-128.
9. Patel S., Sumitra G., Koner B.C., Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem 2011, 44:869-872.
10. Fernandes K.S., Brum D.G., Sandrim V.C., Guerreiro C.T., Barreira A.A., Tanus-Santos J.E. Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol 2009, 214:128-131.
11. Miyazaki S., Kasai T., Miyauchi K., Miyazaki T., Akimoto Y., Takagi A., et al. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J 2010, 74:1158-1164.
12. Sheu J.R., Fong T.H., Liu C.M., Shen M.Y., Chen T.L., Chang Y., et al. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Br J Pharmacol 2004, 143:193-201.
13. Di Simone N., Di Nicuolo F., Sanguinetti M., Ferrazzani S., D'Alessio M.C., Castellani R., et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta 2007, 28:298-304.
14. Jung K., Laube C., Lein M., Lichtinghagen R., Tschesche H., Schnorr D., et al. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998, 44:1060-1062.
15. Jung K., Lein M., Laube C., Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001, 314:241-244.
16. Tayebjee M.H., Lip G.Y., Blann A.D., Macfadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 2005, 115:205-210.
17. Amaro S., Obach V., Cervera A., Urra X., Gómez-Choco M., Planas A.M., et al. Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol 2009, 256:651-656.
18. Jefferis B.J., Whincup P., Welsh P., Wannamethee G., Rumley A., Lennon L., et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010, 208:557-563.
19. Worthmann H., Tryc A.B., Goldbecker A., Ma Y.T., Tountopoulou A., Hahn A., et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 2010, 30:85-92.
20. Castellazzi M., Tamborino C., Fainardi E., Manfrinato M.C., Granieri E., Dallocchio F., et al. Effects of anticoagulants on the activity of gelatinases. Clin Biochem 2007, 40:1272-1276.
21. Gelderblom M., Leypoldt F., Steinbach K., Behrens D., Choe C.U., Siler D.A., et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40:1849-1857.
22. Stevens S.L., Bao J., Hollis J., Lessov N.S., Clark W.M., Stenzel-Poore M.P. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res 2002, 932:110-119.
23. Kouwenhoven M., Carlström C., Ozenci V., Link H. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol 2001, 21:365-375.
24. Tang Y., Xu H., Du X., Lit L., Walker W., Lu A., et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006, 26:1089-1102.
25. McColl B.W., Allan S.M., Rothwell N.J. Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009, 158:1049-1061.
26. Schwettmann L., Wehmeier M., Jokovic D., Aleksandrova K., Brand K., Manns M.P., et al. Hepatic expression of a disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J Hepatol 2008, 49:243-250.
27. Jung K., Klotzek S., Stephan C., Mannello F., Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 2008, 54:772-773.
28. Meisser A., Cohen M., Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005, 51:274-276.
29. Verspaget H.W., Kuyvenhoven J.P., van Hoek B. Preanalytical conditions and circulating matrix metalloproteinases. Transplantation 2005, 79:745-746.
30. Alby C., Ben Abdesselam O., Foglietti M.J., Beaudeux J.L. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin Chim Acta 2002, 325:183-186.
31. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003, 49:339-340.
32. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005, 38:410-414.
33. Mannello F., Jung K., Tonti G.A., Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008, 41:1466-1473.
34. Jung K., Meisser A., Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005, 116:1000-1001.
35. Lim H.S., Lip G.Y. Circulating matrix metalloproteinase-9 levels in atherosclerotic vascular disease: a possible measurement of systemic or specific disease pathophysiology?. J Intern Med 2008, 263:620-622.